在一项大型队列研究中评估 COVID 疫苗接种和感染后的急性肾损伤风险。

IF 6.9 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2024-11-08 DOI:10.1038/s41541-024-00964-3

Yuanyi Pan, Yun Han, Chuan Zhou, Jie Zheng, Lili Zhao, Xianwei Ye, Yongqun He

{"title":"在一项大型队列研究中评估 COVID 疫苗接种和感染后的急性肾损伤风险。","authors":"Yuanyi Pan, Yun Han, Chuan Zhou, Jie Zheng, Lili Zhao, Xianwei Ye, Yongqun He","doi":"10.1038/s41541-024-00964-3","DOIUrl":null,"url":null,"abstract":"Acute kidney injury (AKI) has been noticed after both COVID-19 vaccination and infection, affecting risk-benefit evaluations and vaccine hesitancy. We conducted a large-scale N3C cohort study to compare AKI incidence following COVID-19 vaccination and infection. Participants from December 2020 to August 2023 were divided into two groups based on their initially observed COVID-19 antigen exposure: COVID-19 vaccination group (n = 2,953,219) and COVID-19 infection group (n = 3,616,802). AKI was defined by diagnostic codes and serum creatinine changes within a 30 day follow-up window after exposure. The absolute risk of AKI was 0.66% in the vaccination group versus 4.88% in the infection group. After adjusting for various confounders, COVID-19 infection was associated with a significantly higher risk of AKI than COVID-19 vaccination (aHR = 10.31, P < 0.001). Our study reveals that COVID-19 vaccination is associated with a significant lower AKI risk compared to COVID-19 infection.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"213"},"PeriodicalIF":6.9000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549351/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessing acute kidney injury risk after COVID vaccination and infection in a large cohort study.\",\"authors\":\"Yuanyi Pan, Yun Han, Chuan Zhou, Jie Zheng, Lili Zhao, Xianwei Ye, Yongqun He\",\"doi\":\"10.1038/s41541-024-00964-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Acute kidney injury (AKI) has been noticed after both COVID-19 vaccination and infection, affecting risk-benefit evaluations and vaccine hesitancy. We conducted a large-scale N3C cohort study to compare AKI incidence following COVID-19 vaccination and infection. Participants from December 2020 to August 2023 were divided into two groups based on their initially observed COVID-19 antigen exposure: COVID-19 vaccination group (n = 2,953,219) and COVID-19 infection group (n = 3,616,802). AKI was defined by diagnostic codes and serum creatinine changes within a 30 day follow-up window after exposure. The absolute risk of AKI was 0.66% in the vaccination group versus 4.88% in the infection group. After adjusting for various confounders, COVID-19 infection was associated with a significantly higher risk of AKI than COVID-19 vaccination (aHR = 10.31, P < 0.001). Our study reveals that COVID-19 vaccination is associated with a significant lower AKI risk compared to COVID-19 infection.\",\"PeriodicalId\":19335,\"journal\":{\"name\":\"NPJ Vaccines\",\"volume\":\"9 1\",\"pages\":\"213\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549351/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41541-024-00964-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-00964-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

接种 COVID-19 疫苗和感染后都出现了急性肾损伤 (AKI)，这影响了风险效益评估和疫苗接种的犹豫不决。我们开展了一项大规模 N3C 队列研究，以比较接种 COVID-19 疫苗和感染后的急性肾损伤发生率。根据最初观察到的 COVID-19 抗原暴露情况，将 2020 年 12 月至 2023 年 8 月期间的参与者分为两组：COVID-19 疫苗接种组（n = 2,953,219 人）和 COVID-19 感染组（n = 3,616,802 人）。根据诊断代码和暴露后 30 天随访期内的血清肌酐变化来定义 AKI。疫苗接种组发生 AKI 的绝对风险为 0.66%，而感染组为 4.88%。在对各种混杂因素进行调整后，COVID-19 感染发生 AKI 的风险明显高于 COVID-19 疫苗接种（aHR = 10.31，P<0.05）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Assessing acute kidney injury risk after COVID vaccination and infection in a large cohort study.

Acute kidney injury (AKI) has been noticed after both COVID-19 vaccination and infection, affecting risk-benefit evaluations and vaccine hesitancy. We conducted a large-scale N3C cohort study to compare AKI incidence following COVID-19 vaccination and infection. Participants from December 2020 to August 2023 were divided into two groups based on their initially observed COVID-19 antigen exposure: COVID-19 vaccination group (n = 2,953,219) and COVID-19 infection group (n = 3,616,802). AKI was defined by diagnostic codes and serum creatinine changes within a 30 day follow-up window after exposure. The absolute risk of AKI was 0.66% in the vaccination group versus 4.88% in the infection group. After adjusting for various confounders, COVID-19 infection was associated with a significantly higher risk of AKI than COVID-19 vaccination (aHR = 10.31, P < 0.001). Our study reveals that COVID-19 vaccination is associated with a significant lower AKI risk compared to COVID-19 infection.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.